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Abstract
Aim of this commentary is to report the most recent views about natural history of subclinical hypothyroidism (SH)
according to the different etiologies. In children with idiopathic SH the natural evolution is often favourable, with a
high percentage of cases reverting to euthyroidism or remaining SH even after a prolonged follow-up. By contrast,
the risk of a significant deterioration of thyroid status is distinctly higher in the SH children with Hashimoto’s
thyroiditis (HT). This risk is even higher in the cases with both HT-related SH and chromosomal abnormalities, such
as Turner or Down’s syndrome.
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Background
Subclinical hypothyroidism (SH) is a biochemical condition
characterized by serum TSH concentrations above the
upper limit of the reference range and serum FT4 levels
within the reference range [1]. Although its prevalence is
generally reported to be higher in the elderly population,
this condition may be quite common even in children and
adolescents and pediatric endocrinologists frequently face
the decision of what to do regarding SH children [2].
Data concerning the natural course of this condition in
pediatric patients are controversial, probably due to the fact
that it may be significantly conditioned by the different
etiologies. SH, in fact, may be possibly caused by the same
thyroid diseases which result in overt thyroid function
impairment and, particularly, Hashimoto’s thyroiditis (HT)
[3, 4]. However, in most cases no definite etiology can be
detected (idiopathic SH).
The aims of this commentary are to summarize the most
recent views about natural evolution of SH in childhood
and to analyze the most important predictive factors for its
progression over time.
Predictive factors for SH progression
The natural history of SH may be the reversion to euthyr-
oidism or the persistence over time or the progression to
frank hypothyroidism (with reduced FT4 levels).
In adults the risk of a progression toward overt
hypothyroidism seems to be higher [5, 6] than that
generally reported in children and adolescents [7–12].
In fact, in most of the available pediatric studies the
rate of development of a frank hypothyroidism ranges
between 0 and 28.8%, whereas the majority of initially
SH patients revert to euthyroidism or remain SH [13].
The initial presence of goiter and elevated thyroglobu-
lin autoantibodies, the coexistence of celiac disease and
a progressive increase in the serum values of thyro-
peroxidase autoantibodies and TSH may be predictive
of evolution toward thyroid failure [12, 14].
However, from the analysis of pediatric literature, it
emerges that baseline TSH levels are probably the most
powerful predictors of SH evolution over time [10, 15].
In fact, children with high baseline TSH concentrations
are likely to need supranormal amounts of TSH to ad-
equately stimulate the thyroid and, therefore, the persist-
ence over time of a SH status is not surprising in these
children [10, 15].* Correspondence: filippo.deluca@unime.it
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Other factors which can play a significant role in condi-
tioning the natural course of SH in children seem to be the
etiology (either idiopathic or secondary to HT or obesity)
and a possible association with either Turner syndrome
(TS) or Down’s syndrome (DS), i.e., two chromosomopa-
thies that are known to be linked with an increased risk of
autoimmune thyroid diseases (AITDs) [16].
Natural course of idiopathic SH
Pediatric studies on long-term evolution of SH in indi-
viduals with no apparent underlying thyroid disorders
are few [10, 11, 17, 18].
In the retrospective and large study by Lazar et al. [10],
TSH values during a 5-year follow-up tended to normalize
over time, proportionally to the degree of TSH elevation
at the onset of investigation. Predictive factors for a deteri-
oration over time of thyroid function tests were an initial
TSH value > 7.5 mIU/l and female gender, whilst age was
not found to play a predictive role [10].
In the prospective multicenter study by Wasniewska
et al. [11], based on a 2-year follow-up, 41.3% of the
initially SH children normalized their TSH over time,
whereas 58.7% remained SH and 12% increased TSH
to >10 mIU/l. None of these children showed any
symptoms of hypothyroidism during follow-up [11].
In the prospective study by Cerbone et al. [17], no
alterations in growth, bone maturation, body mass index
status and cognitive functions were observed, during a
period of 2.0–9.3 years, in a series of children with idio-
pathic SH. These findings suggest that thyroid hormones
involved in growth and neurocognitive development seem
to be able to work properly, regardless of the persistently
elevated TSH [2].
Finally, also the results of another five-year prospective
study confirm that the natural history of idiopathic SH in
pediatric age is characterized by a favourable long-term
prognosis [18]. In fact, the majority of children with idio-
pathic SH (61.9%) spontaneously normalized over time their
TSH values and only a minority (11.9%) became overtly
hypothyroid at the end of follow-up (Fig. 1). By contrast,
only a small minority (10.6%) of the patients who had pre-
sented with HT-related SH spontaneously normalized their
TSH at the end of follow-up, whilst the majority remained
SH or developed an overt hypothyroidism. On overall, these
results confirm, on the basis of a prolonged prospective
examination [18], the recent inference that underlying HT
negatively affects the natural evolution of SH in children,
irrespective of other concomitant risk factors [14].
As the majority of prospective pediatric studies dem-
onstrate that idiopathic SH is often a remitting or self-
limiting process, thyroid function monitoring in these
children should not be performed too frequently: every
12 months, according to the recent guidelines of the
European Thyroid Association [19].
A controversial issue in the management of children
with idiopathic SH is whether these cases should be
treated or not. The evidence for benefit of L-T4 supple-
mentation is poor [15], although this does not necessar-
ily imply lack of benefit [20]. If there is an underlying
HT, treatment might be taken into consideration, since
progression from SH to overt hypothyroidism is more
likely in these cases [12, 14, 18].
Natural course of HT- related SH
Thyroid function at HT presentation may significantly vary
in the different pediatric cohorts [8, 9, 21–23]. In children
Fig. 1 Prevalence (%) of the main biochemical pictures of thyroid function detected, at the end of a 5-year follow-up, in two groups of children
who presented with either idiopathic subclinical hypothyroidism (SH) (Group A) or Hashimoto’s thyroiditis (HT)-related SH (Group B) (according to
the results of Reference 18 study)
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euthyroidism is the most frequent presenting pattern,
followed by SH and overt hypothyroidism [24]. Further and
less frequent complaints of thyroid function which may be
observed in children, at HT presentation, include either
overt or subclinical hyperthyroidism [25, 26].
Thyroid function at HT diagnosis is mainly conditioned
by patients’ age, with an increased risk of thyroid dysfunc-
tions in the youngest children [4, 24].
In children and adolescents with HT, also the evolu-
tion over time of thyroid status may be quite variable
[7, 9, 22, 27, 28] and is significantly affected by TSH
serum levels at the time of HT diagnosis [7, 15].
According to the results of a recent report, a trend
toward a progressive deterioration of thyroid status may be
observed both in the initially euthyroid children and in
those presenting with SH, although it has to be underlined
that thyroid status prognosis in children with HT is not
necessarily unfavourable [29]. In fact, at the end of a 5-year
follow-up, 57.1% of the patients who had presented with
euthyroidism remained euthyroid and 40.6% of those who
were initially SH spontaneously normalized their thyroid
function [29]. The results of that study, however, suggest
that the patients presenting with SH may be more incline
to develop over time a severe thyroid dysfunction picture,
if compared with those presenting with euthyroidism [29].
In the light of the results of these studies on the nat-
ural course of thyroid status in children with HT- related
SH, it might be proposed that thyroid function monitor-
ing in these cases should be more strict than in children
with idiopathic SH: every 6 months [30].
In the cases exhibiting a deterioration over time of
thyroid status the hypothesis of a supplementation with
L-T4 could not be preliminarily excluded, particularly
considering the encouraging data reported by Svensson
et al. [31]. These authors, in fact, in their retrospective
study on 42 Swedish children with HT-related SH,
found a significant reduction in median thyroid volume
following a 2-year treatment with L-T4 [31].
Natural course of HT-related SH in Turner syndrome (TS)
TS, that is one of the commonest chromosomal abnormal-
ities, is known to be associated with an increased risk of
developing AITDs and also celiac disease, type 1 diabetes,
vitiligo and juvenile idiopathic arthritis [32–37].
In TS girls HT is by far the commonest autoimmune dis-
ease, with a relative prevalence which has been reported to
be even more elevated than that generally reported in age-
matched girls without TS [32, 34, 35]. Also the other one
AITD, i.e., Graves’ disease (GD), has been reported to be
distinctly more frequent in TS girls than in the pediatric
general population [32, 38–40].
The spontaneous evolution over time of thyroid function
tests in TS girls with HT seems to be characterized by a
significant worsening of thyroid status, both in the children
presenting with euthyroidism and in those presenting with
SH [41]. This spontaneous trend is especially evident in the
TS girls with initial SH and is irrespective of both karyotype
and other factors [42]. This inference was, just recently,
supported by a 5-year prospective study [18], which con-
firmed that the association with TS is able to affect the
course of HT, by increasing the risk of a thyroid function
deterioration over time [18]. According to the results of
that study [18], in fact, none of TS girls with HT-related SH
reverted to euthyroidism, at the end of follow-up and the
majority progressed to overt hypothyroidism (Fig. 2). Such
Fig. 2 Prevalence (%) of the main biochemical pictures of thyroid function detected, at the end of a 5-year follow-up, in three subgroups of children with
Hashimoto’s thyroiditis (HT)-related subclinical hypothyroidism without chromosomopathies (Subgroup B1) or with Turner syndrome (Subgroup B2) or
Down’s syndrome (Subgroup B3) (according to the results of Reference 18 study)
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an evolution pattern was distinctly more severe when com-
pared with that recorded in the children with HT-related
SH but without TS (Fig. 2).
To sum up, in the light of these peculiarities that
characterize the natural course of TS-related HT, all indi-
viduals with TS should require continued monitoring of
thyroid function throughout the life-span, as suggested by
the TS Consensus Study Group [43].
Natural course of HT-related SH in Down’s syndrome (DS)
DS is another relatively common chromosomopathy,
which is known to be associated with an increased
prevalence of AITDs [16]. In fact, both HT and GD
may be encountered relatively often in the clinical his-
tory of DS children, probably due to a dysregulation of
immune system, with secondary impairment of inhibi-
tory activity [44]. This hypothesis could explain the
common link with other extra-thyroidal autoimmune
disorders [45, 46], which may be found in around 65%
of DS children [47]. Among these diseases, the one that
is most typically associated with DS is alopecia [48].
SH is common in DS children and should not be neces-
sarily interpreted as consequence of HT. In fact, it might
also result from a congenital alteration in the regulation of
thyroid function [47], which has been reported to be pecu-
liar of DS [49, 50].
Natural evolution of HT-related SH in DS children has
been, just recently, investigated by means of a 5-year
follow-up study [18]. In the light of the results of that pro-
spective study, the association with DS might be able to
condition a peculiar biochemical course of HT [18]. In
fact, if the thyroid function biochemical patterns at the
end of follow-up were compared with the ones found in
the same DS children 5 years earlier, the almost totality of
patients maintained a SH picture and only a minority of
them reverted to euthyroidism or progressed to overt
hypothyroidism [Fig. 2]. It is also noteworthy that, in 7.1%
of DS children with HT-related SH, HT switched over
time to GD [18]. This is not surprising, considering that DS
children might be prone to manifest over time a phenotypic
metamorphosis from HT to GD and to subsequently fluc-
tuate from hypothyroidism to hyperthyroidism [51].
Finally, a further phenotypical peculiarity of DS
patients is that clinical expression of autoimmunity in
these individuals may be particularly severe [52].
SH and obesity
Abnormalities of thyroid function are a frequent finding in
obese children [53]. In particular, a SH may be encountered
in 7.5% of these individuals [53]. The severity of SH in
obese children is mainly conditioned by the level of over-
weight, whilst the distribution of patients with SH is not
different between sexes and between prepubertal and
pubertal individuals [53].
The pathophysiological mechanisms responsible for SH
in obesity are not clear, although a role of leptin has been
proposed [53]. In fact, serum leptin levels are increased in
obese patients and some reports suggest that leptin can
affect the hypothalamic regulation of TSH production
[54]. However, since SH often reverts after weight loss, it
seems to be a reversible complication of the overweight
status and has not to be considered as a cause of obesity
[53]. Therefore, any hormonal treatment should be
avoided in obese children and also monitoring of thyroid
function in these cases should not be too strict, since the
risk of a progression toward overt hypothyroidism is not
high. In fact, it has to be considered that FT3 serum levels
are frequently increased in obese children, probably due
to an adaptation process secondary to weight gain [53].
This should preserve obese children with SH from the risk
of developing an overt hypothyroidism.
Conclusions
Long-term prognosis of mild and idiopathic SH is fre-
quently benign. The evidence for benefit of L-T4 supple-
mentation is poor, although this does not necessarily
imply lack of benefit. If there is an underlying HT, thy-
roid function monitoring has to be more strict, since
progression from SH to overt hypothyroidism is more
likely in these cases.
The association with either TS or DS furtherly impairs
the outcome of HT-related SH.
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